Key Takeaways
- Sitryx Therapeutics announces participation in two upcoming investor conferences in November 2025.
- The company is developing oral therapies to address autoimmune and inflammatory diseases.
- Potential first-in-class drug SYX-5219 is being explored for atopic dermatitis and other autoimmune conditions.
Upcoming Investor Conferences
Sitryx Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two significant investor conferences set for November 2025. The first event is the Wells Fargo Virtual Private Biotech Symposium on November 5, featuring virtual one-on-one meetings. The second event is the Stifel 2025 Healthcare Conference on November 12, where Sitryx will present at 8:00 AM ET and engage in both group and one-on-one meetings.
Investors interested in scheduling meetings can contact their respective Wells Fargo and Stifel representatives. Additionally, a webcast of the Stifel presentation will be available on the Sitryx website under the News & Events section.
About Sitryx Therapeutics
Sitryx specializes in developing innovative oral therapies that aim to restore immune balance for those suffering from autoimmune and inflammatory diseases. The company boasts a diverse pipeline of small molecule candidates targeting significant autoimmune conditions where there is a pressing need for effective treatments.
Its lead candidate, SYX-5219, is a potentially groundbreaking PKM2 modulator currently in development as a once-daily oral therapy for atopic dermatitis. There is also potential for its application across various autoimmune diseases.
Founded in 2018, Sitryx is backed by a consortium of specialized investors, including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly, and GSK. The company operates out of headquarters in Oxford, UK, with additional facilities in Boston, MA. For further details, visit the official Sitryx website at www.sitryx.com.
The content above is a summary. For more details, see the source article.
